mirtazapine has been researched along with Mental Disorders in 17 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 6.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| " The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)." | 4.12 | Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022) |
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 2.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "Mirtazapine (7." | 1.48 | Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia. ( Poyurovsky, M; Weizman, A, 2018) |
| "Mirtazapine is an antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission." | 1.40 | Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ( Jang, JH; Kim, DK; Lee, SY; Myung, W; Yoon, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Ciccarone, D | 1 |
| Shoptaw, S | 1 |
| Hefner, G | 1 |
| Wolff, J | 1 |
| Toto, S | 1 |
| Reißner, P | 1 |
| Klimke, A | 1 |
| Al-Khalil, M | 1 |
| Sack, A | 1 |
| Elson, R | 1 |
| Pleat, J | 1 |
| Poyurovsky, M | 2 |
| Weizman, A | 2 |
| Hutchins, D | 1 |
| Hall, J | 1 |
| Sharma, A | 1 |
| Shinozaki, M | 1 |
| Pierce, J | 1 |
| Hayashi, Y | 1 |
| Watanabe, T | 1 |
| Sasaki, T | 1 |
| Komahashi-Sasaki, H | 1 |
| Akiyama, K | 1 |
| Kato, K | 1 |
| Inoue, Y | 1 |
| Tsuchimine, S | 1 |
| Yasui-Furukori, N | 1 |
| Ozeki, Y | 1 |
| Shimoda, K | 1 |
| Myung, W | 1 |
| Jang, JH | 1 |
| Yoon, H | 1 |
| Lee, SY | 1 |
| Kim, DK | 1 |
| Paulzen, M | 1 |
| Gründer, G | 1 |
| Tauber, SC | 1 |
| Veselinovic, T | 1 |
| Hiemke, C | 1 |
| Groppe, SE | 1 |
| Grover, S | 1 |
| Avasthi, A | 1 |
| Tripathi, A | 1 |
| Tanra, AJ | 1 |
| Chee, KY | 1 |
| He, YL | 1 |
| Chiu, HF | 1 |
| Kuga, H | 1 |
| Lee, MS | 1 |
| Chong, MY | 1 |
| Udormatn, P | 1 |
| Kanba, S | 1 |
| Yang, SY | 1 |
| Si, TM | 1 |
| Sim, K | 1 |
| Tan, CH | 1 |
| Shen, WW | 1 |
| Xiang, YT | 1 |
| Sartorius, N | 1 |
| Shinfuku, N | 1 |
| Li, TC | 1 |
| Shiah, IS | 1 |
| Sun, CJ | 1 |
| Tzang, RF | 1 |
| Huang, KC | 1 |
| Lee, WK | 1 |
| Banerjee, S | 1 |
| Hellier, J | 1 |
| Dewey, M | 1 |
| Romeo, R | 1 |
| Ballard, C | 1 |
| Baldwin, R | 1 |
| Bentham, P | 1 |
| Fox, C | 1 |
| Holmes, C | 1 |
| Katona, C | 1 |
| Knapp, M | 1 |
| Lawton, C | 1 |
| Lindesay, J | 1 |
| Livingston, G | 1 |
| McCrae, N | 1 |
| Moniz-Cook, E | 1 |
| Murray, J | 1 |
| Nurock, S | 1 |
| Orrell, M | 1 |
| O'Brien, J | 1 |
| Poppe, M | 1 |
| Thomas, A | 1 |
| Walwyn, R | 1 |
| Wilson, K | 1 |
| Burns, A | 1 |
| Juckel, G | 2 |
| Schüle, C | 1 |
| Pogarell, O | 2 |
| Rupp, D | 1 |
| Laakmann, G | 1 |
| Hegerl, U | 2 |
| Kozyrev, VN | 1 |
| Smulevich, AB | 1 |
| Drobizhev, MIu | 1 |
| Kraeva, GK | 1 |
| Kubrakov, MA | 1 |
| Szegedi, A | 1 |
| Schwertfeger, N | 1 |
| Zullino, D | 1 |
| Mayland, G | 1 |
| Schmidt, LG | 1 |
| Fähndrich, E | 1 |
| Greil, W | 1 |
| Horvath, A | 1 |
| Rüther, E | 1 |
| Engel, R | 1 |
| Hippius, H | 1 |
| Baumann, P | 1 |
| Pashinian, A | 1 |
| Weizman, R | 1 |
| Fuchs, C | 1 |
| Sterr, A | 1 |
| Padberg, F | 1 |
| Amann, B | 1 |
| Mergl, R | 1 |
| Mulert, C | 1 |
4 reviews available for mirtazapine and Mental Disorders
| Article | Year |
|---|---|
Understanding Stimulant Use and Use Disorders in a New Era.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Anticonvulsants; Behavior Therapy; Bupropion; Centra | 2022 |
Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Fema | 2011 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Mirtazapine: a review of its clinical efficacy and tolerability.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Mental Disorder | 2005 |
2 trials available for mirtazapine and Mental Disorders
| Article | Year |
|---|---|
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Anti-Anxiety Agents; Antidepressive Agents, Tr | 2006 |
12 other studies available for mirtazapine and Mental Disorders
| Article | Year |
|---|---|
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders | 2022 |
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Arrhythmias, Cardiac; Burns; Comorbidity; Drug Int | 2020 |
Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Humans; Male; Mental Disorders; Middle | 2018 |
Mirtazapine-Induced Transient Dyskinesia.
Topics: Antidepressive Agents; Dyskinesia, Drug-Induced; Female; Humans; Mental Disorders; Middle Aged; Mirt | 2019 |
8-Hydroxylation and Glucuronidation of Mirtazapine in Japanese Psychiatric Patients: Significance of the Glucuronidation Pathway of 8-Hydroxy-Mirtazapine.
Topics: Age Factors; Alleles; Anti-Anxiety Agents; Asian People; Cytochrome P-450 CYP2D6; Genotype; Glucuron | 2019 |
Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Drug Monit | 2014 |
Distribution pattern of mirtazapine and normirtazapine in blood and CSF.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Blood-Brain Barrier; Female; Humans; Male; Mental Dis | 2015 |
Antidepressant Prescription Pattern in the Presence of Medical Co-morbidity: REAP-AD 2013 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; | 2015 |
Epileptiform EEG patterns induced by mirtazapine in both psychiatric patients and healthy volunteers.
Topics: Adult; Antidepressive Agents; Electroencephalography; Epilepsy; Female; Humans; Mental Disorders; Mi | 2003 |
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepin | 2003 |
Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Community Mental Health Centers; Drug Presc | 2005 |
Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Electroence | 2006 |